<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189410</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-GYN 3</org_study_id>
    <nct_id>NCT00189410</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours</brief_title>
  <official_title>Phase II Trial With Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin (PLD) and Carboplatin in Malignant Gynecologic Tumour's</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedServ. GmbH, Wiesbaden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Essex Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AGO Study Group</source>
  <brief_summary>
    <textblock>
      Pegylated Liposomal Doxorubicin as well as Carboplatin have been showed efficacy in
      monotherapy as in combination therapy of gynaecologic tumours. As there is no common standard
      in the therapy of recurrent ovarian carcinoma, tumours of the uterus nor for non-epithelial
      ovarian tumours at time of designing of this study, this trial shall evaluate the new and
      well tolerated combination therapy consisting of Pegylated Liposomal Doxorubicin and
      Carboplatin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of these study is the evaluation of combination chemotherapy in a patient subset with
      gynecologic tumours on regard to tolerance and efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate mainly in malignant uterine tumours</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression mainly in malignant uterine tumours</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival mainly in malignant uterine tumours</measure>
  </secondary_outcome>
  <enrollment type="Actual">140</enrollment>
  <condition>Cancer of the Ovary Treated as 2nd Line Therapy</condition>
  <condition>Muellerian Mixed Tumours</condition>
  <condition>Tumours of the Uterus</condition>
  <condition>Cervical Cancers</condition>
  <condition>Non-Epithelial Ovarian Tumours</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin and Carboplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of a gynecologic tumour [(non-epithelial ovarian
             tumour without germcell-tumours, tumours of the uterus (eg. Muellerian mixed tumours,
             Endometrial carcinomas, Uterus sarcoma, Cancer of the cervix)]

          -  Target or non-target lesion. Patients with epithelial ovarian carcinoma are qualified
             also if they have a CA 125 increase only.

          -  Patients with ovarian carcinoma must have completed a platin-containing chemotherapy
             more than 6 months at least. Patients with other malignancies could have prior
             chemotherapy, but must'nt

          -  Prior Radiotherapy less than 25% of haemapoietic system is allowed, but should have
             completed at least 6 weeks prior or registration

          -  Prior antitumoral hormone therapy, or specific immunotherapy is allowed, treatment
             have to be completed at least 3 weeks prior of registration

          -  All women with childbearing potential have to be a negative pregnancy test within 7
             days of registration

          -  Perfomance Status 0-2 ECOG or more than 60% according to Karnofsky Index

          -  Estimated expectancy of life of more than 12 weeks

          -  adequate hematologic, renal and hepatic function according to following definitions:
             absolute Neutrophils &gt;= 1,5 n/L Platelets &gt;= 100 n/L Bilirubine &lt;= 1,25 x ULN
             estimated glomerular filtration rate (Jelliffe) &gt;= 60 ml/min

          -  Patients who have given their signed and written informed consent to participate in
             the trial

          -  Patients must be geographically accessible for treatment and follow

        Exclusion Criteria:

          -  More than 2 prior chemotherapies (or Radio-Chemotherapies)

          -  active infection or concurrent severe medical problems unrelated to malignancy which
             would significantly limit full compliance with the study or expose the patient to
             extreme risk or decreased life expectancy

          -  application of other cytotoxic or antitumoral agents during study period

          -  Patients with a history of seizure disorder or central nervous system disorders

          -  History of congestive heart failure (NYHA Classification &gt; 2, even if medically
             controlled.

          -  History of clinical and electrocardiographically documented myocardial infarction
             within the last 6 months.

          -  History of atrial or ventricular arrhythmias (&gt; LOWN II)

          -  Women who are pregnant or breast feeding

          -  Fertile women not using adequate contraceptive measures

          -  Patients who have used any investigational drugs within 30 days of study entry
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas du Bois, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AGO-OVAR, AGO Ovarian Cancer Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Practice Dr. Klare</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus, Dept. of Gynecology &amp; Obstetrics</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerisity Hospital; Dept. of Gynecology &amp; Obstetrics</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital, Dept. of gynecology &amp; obstetrics</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital , Dept. gynecologic &amp; obestretics</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Freiburg; Dept of Gynecology &amp; Obstetrics</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ernst-Moritz-Arndt University, Dept. of Gynecology &amp; Obstetrics</name>
      <address>
        <city>Greifswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MH Hannover, Dept. of Gynecology &amp; Obstetrics</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Hospital, Dept. of Gynecology &amp; Obstetrics</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerisity Clinic Schleswig-Holstein, Campus Kiel, Dept. for gynecology &amp; obstetrics</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke Univerisity, Dept. of Gynecology &amp; Obstetrics</name>
      <address>
        <city>Magdeburg</city>
        <zip>39108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital, Dept. of Gynecology &amp; Obstetrics</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phillips University, Clinic fo gynecology, gyn endocrinology and oncology</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital Muenchen-Grosshadern, Dept. of gynecology &amp; obstetrics</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital TU Muenchen; Dept. of Gynecology &amp; Obstetrics</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humaine Vogtlandklinikum; Dept. of gynecology &amp; obstetrics</name>
      <address>
        <city>Plauen</city>
        <zip>08529</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital, Dept. gynecology &amp; obstetrics</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum Villingen, Dept. Gynecology</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HSK, Dr. Horst Schmidt Klinik, Dept. of Gynecology &amp; Gyn. Oncology</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ago-ovar.de</url>
    <description>Homepage of the AGO Ovarian Cancer Study Group</description>
  </link>
  <reference>
    <citation>Gropp M, du Bois A, Burges A, Meier W. Combination of Pegliposomal Doxorubicin (PLD) and Carboplatin in gynecologic tumors - An AGO Study Group Phase I/II trial. Int J Gycecol Cancer 2003:13 Suppl 1, p 112</citation>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>July 19, 2010</last_update_submitted>
  <last_update_submitted_qc>July 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Gabriele Elser</name_title>
    <organization>MedServ. GmbH, Wiesbaden</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

